(Q38102825)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23628309%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

title

Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23628309%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23628309%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

author name string

Donald Lamm

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23628309%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Maurizio Brausi

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23628309%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

J Alfred Witjes

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23628309%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

publication date

28 April 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23628309%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23628309%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23628309%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23628309%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

page(s)

35.e21-30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23628309%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

cites work

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.02.010

A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.02.010

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.02.010

Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.02.010

A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.02.010

A randomized comparative dose-ranging study of interferon-alpha and mitomycin-C as an internal control in primary or recurrent superficial transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.02.010

Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and [...]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.02.010

Efficacy of escalating doses of intravesical interferon alpha-2b in reducing recurrence rate and progression in superficial transitional cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.02.010

Results at 43 months' follow-up of a double-blind, randomized, prospective clinical trial using intravesical interferon alpha-2b in the prophylaxis of stage pT1 transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.02.010

Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: results of a multicentric Italian study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.02.010

Intravesical immunoprophylaxis in recurrent superficial bladder cancer (Stage T1): multicenter trial comparing bacille Calmette-Guérin and interferon-alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.02.010

New insights in intravesical treatment for intermediate- and high-risk non-muscle-invasive urothelial bladder carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.02.010

Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.02.010

Maintenance therapy with bacillus Calmette-Guérin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.02.010

Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.02.010

Long-term results of intravesical bacillus Calmette-Guérin therapy for stage T1 superficial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.02.010

Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.02.010

Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.02.010

Intravesicle gemcitabine in management of BCG refractory superficial TCC of urinary bladder-our experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.02.010

Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.02.010

Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.02.010

Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.02.010

Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.02.010

Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.02.010

Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.02.010

Superficial bladder cancer therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.02.010

Combined bacillus Calmette-Guerin and interferon use in superficial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.02.010

Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.02.010

Intravesical bacille Calmette-Guérin induces the antiangiogenic chemokine interferon-inducible protein 10.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.02.010

Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guérin-induced antitumor activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.02.010

Prophylactic intracavitary treatment with interferon alpha increases interferon gamma production by peripheral blood mononuclear cells in patients with superficial transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.02.010

Effects of bacillus Calmette-Guèrin and interferon alpha-2B on cytokine production in human bladder cancer cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.02.010

Interferon-alpha induces TRAIL expression and cell death via an IRF-1-dependent mechanism in human bladder cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.02.010

Serum Th1 and Th2 cytokine balance in patients of superficial transitional cell carcinoma of bladder pre- and post-intravesical combination immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.02.010

Pharmacological biocompatibility between intravesical preparations of BCG and interferon-alpha 2B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.02.010

Bacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.02.010

Bacillus Calmete-Guérin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.02.010

Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.02.010

Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.02.010

The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.02.010

Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.02.010

Factors affecting response to bacillus Calmette-Guérin plus interferon for urothelial carcinoma in situ

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.02.010

Diminished efficacy of Bacille Calmette-Guérin among elderly patients with nonmuscle invasive bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.02.010

10.1016/J.UROLONC.2013.02.010

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23628309%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference